
Search Clinical Trials
Sponsor Condition of Interest |
---|
Impact of Metformin on Immunity
The University of Texas Health Science Center at San Antonio
Aging
Vaccine Response Impaired
To determine whether metformin (MET) can improve the immune response to the pneumococcal
conjugate vaccine (PCV-13) in older adults.
expand
To determine whether metformin (MET) can improve the immune response to the pneumococcal conjugate vaccine (PCV-13) in older adults. Type: Interventional Start Date: Jan 2019 |
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma...
National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Renal Cell Carcinoma
This phase II trial studies how well axitinib and nivolumab work in treating patients with
TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or
has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor... expand
This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE/translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy. Type: Interventional Start Date: Oct 2018 |
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
Immunomedics, Inc.
Urothelial Carcinoma
This is an international, multi-center, open-label, phase II study in patients with
metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1
based immunotherapy.
At least 201 patients are anticipated to be enrolled across approximately 40... expand
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 201 patients are anticipated to be enrolled across approximately 40 sites from North America and Europe. Type: Interventional Start Date: Aug 2018 |
Daily Study of Caregiving Relationships and Health
The University of Texas Health Science Center at San Antonio
Caregiver Burnout
Dementia
Dementia of Alzheimer Type
Relations, Family
Social Stress
The purpose of the Daily Study of Caregiving Relationships and Health is to learn how
caregiving relationships and social connectedness are associated with dementia caregivers'
health, health behaviors, and diurnal patterns of salivary cortisol.
This is a pilot study wherein... expand
The purpose of the Daily Study of Caregiving Relationships and Health is to learn how caregiving relationships and social connectedness are associated with dementia caregivers' health, health behaviors, and diurnal patterns of salivary cortisol. This is a pilot study wherein the purpose is to test the feasibility and acceptability of study protocols. Type: Observational Start Date: Sep 2020 |
Retention of Nasoenteric Feeding Tubes in Pediatric Patients Using a Nasal Bridle
The University of Texas Health Science Center at San Antonio
Feeding Tube Complication
A study to compare tube dislodgment rates when a nasoenteric feeding tube is secured with
adhesive tape vs the AMT BridlePro device.
expand
A study to compare tube dislodgment rates when a nasoenteric feeding tube is secured with adhesive tape vs the AMT BridlePro device. Type: Interventional Start Date: Feb 2020 |
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Children's Oncology Group
Desmoid-Type Fibromatosis
Recurrent Desmoid-Type Fibromatosis
Unresectable Desmoid-Type Fibromatosis
This phase II trial studies the side effects and how well nirogacestat works in treating
patients with desmoid tumors that has grown after at least one form of treatment by mouth or
in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor
cells... expand
This phase II trial studies the side effects and how well nirogacestat works in treating patients with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Type: Interventional Start Date: Sep 2020 |
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood...
Children's Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
This phase III trial compares a multi-component mobile health and social media physical
activity intervention versus wearing a physical activity tracker alone among adolescent and
young adult childhood cancer survivors. Regular physical activity helps maintain healthy
weight,... expand
This phase III trial compares a multi-component mobile health and social media physical activity intervention versus wearing a physical activity tracker alone among adolescent and young adult childhood cancer survivors. Regular physical activity helps maintain healthy weight, energy levels, and health. Adolescents and young adults who complete treatment for cancer are often less active. They may gain weight and have more health problems compared to people the same age who have not had treatment for cancer. Comparing the 2 programs will help researchers learn how to increase physical activity levels over time and also how changes in physical activity levels affect health and quality of life over time. Type: Interventional Start Date: Jan 2021 |
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult...
Children's Oncology Group
Childhood Extracranial Germ Cell Tumor
Extragonadal Embryonal Carcinoma
Germ Cell Tumor
Malignant Germ Cell Tumor
Malignant Ovarian Teratoma
This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide,
or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active
surveillance may help doctors to monitor subjects with low risk germ cell tumors after their... expand
This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Type: Interventional Start Date: May 2017 |
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine...
ECOG-ACRIN Cancer Research Group
Gastric Neuroendocrine Carcinoma
Intestinal Neuroendocrine Carcinoma
Pancreatic Neuroendocrine Carcinoma
This randomized phase II trial studies how well temozolomide and capecitabine work compared
to standard treatment with cisplatin or carboplatin and etoposide in treating patients with
neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other... expand
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current standard treatment of cisplatin and etoposide. It is not yet known whether temozolomide and capecitabine may work better than cisplatin or carboplatin and etoposide in treating patients with this type of neuroendocrine carcinoma, called non-small cell neuroendocrine carcinoma. Type: Interventional Start Date: Nov 2015 |
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Pfizer
Venous Thromboembolism
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring
anticoagulation for the treatment of a VTE.
expand
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE. Type: Interventional Start Date: Nov 2015 |
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Glioma
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of
the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to
patients with recurrent or progressive malignant glioma after standard surgical, radiation,... expand
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL. Type: Interventional Start Date: Jun 2015 |
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate...
Rockwell Medical Technologies, Inc.
End Stage Renal Disease
The main purpose is to determine the safety of Triferic iron administered via dialysate and
intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis
(CKD-5HD). It is a global, multi- center, open-label study.
expand
The main purpose is to determine the safety of Triferic iron administered via dialysate and intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is a global, multi- center, open-label study. Type: Interventional Start Date: Jun 2020 |
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1...
National Cancer Institute (NCI)
Recurrent Ependymoma
Recurrent Ewing Sarcoma
Recurrent Hepatoblastoma
Recurrent Langerhans Cell Histiocytosis
Recurrent Malignant Germ Cell Tumor
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients
with solid tumors that have spread to other places in the body (advanced), lymphoma, or
histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block
the... expand
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway. Type: Interventional Start Date: Jun 2020 |
Reducing the Abuse of Opioids in Drug Users
The University of Texas Health Science Center at San Antonio
Opioid Abuse, Unspecified
Opioid Dependence
The consequences of prescription opioid abuse are serious and the number of deaths from
unintended overdose have quadrupled over the last 15+ years. Opioid analgesics remain among
the most commonly abused class of substances in the United States. Moreover, patients who
take... expand
The consequences of prescription opioid abuse are serious and the number of deaths from unintended overdose have quadrupled over the last 15+ years. Opioid analgesics remain among the most commonly abused class of substances in the United States. Moreover, patients who take pain medications for legitimate reasons may develop an opioid use disorder (OUD), with as many as 1 in 4 patients becoming dependent on their pain medications. Because of changing access to prescription opioid analgesics due to an increasingly negative prescribing climate and changes in guidelines, patients often turn to heroin, with an estimated 1 in 15 pain patients trying heroin within 10 years. Pain is a symptom that can be severely debilitating and needs to be treated adequately to improve the quality of life. Clinicians, then, are in a proverbial "catch-22" situation whereby treating a patient's chronic pain also exposes them to medications with substantial abuse liability and overdose risk. In this proposal, a method aimed at reducing the abuse potential of prescription opioid medications, without altering their analgesic efficacy, is described. The study team hypothesize that this can be accomplished by administering a fixed-dose-combination of an opioid with an atypical antipsychotic drug, in the same pill or capsule. Type: Interventional Start Date: Apr 2019 |
Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology
The University of Texas Health Science Center at San Antonio
Congenital Heart Defect
A randomized, blinded, controlled trial to evaluate growth velocity and clinical outcomes in
infants with single ventricle physiology fed an exclusive human milk diet prior to, and
throughout the post-operative period following, surgical repair. Human milk is defined as
expressed... expand
A randomized, blinded, controlled trial to evaluate growth velocity and clinical outcomes in infants with single ventricle physiology fed an exclusive human milk diet prior to, and throughout the post-operative period following, surgical repair. Human milk is defined as expressed human milk or donor milk and its derivatives, human milk-based fortifier and human milk caloric fortifier. The study hypothesis is that infants fed an exclusive human milk diet will have short and long term benefits, with improved wound healing, growth, and neurodevelopmental outcomes while reducing episodes of feeding intolerance and necrotizing enterocolitis (NEC). Type: Interventional Start Date: Jul 2016 |
Effects of Creatine Supplementation in Breast Cancer Survivors
The University of Texas Health Science Center at San Antonio
Breast Cancer
Chemotherapy Effect
Muscle Weakness
Muscle Loss
Exercise
The purpose of this study is to test the hypothesis that creatine will accelerate adaptations
associated with exercise in breast cancer survivors recently completing chemotherapy.
expand
The purpose of this study is to test the hypothesis that creatine will accelerate adaptations associated with exercise in breast cancer survivors recently completing chemotherapy. Type: Interventional Start Date: Sep 2020 |
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients...
Children's Oncology Group
High Risk Neuroblastoma
Recurrent Ganglioneuroblastoma
Refractory Ganglioneuroblastoma
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab
work with or without eflornithine in treating patients with neuroblastoma that has come back
(relapsed) or that isn't responding to treatment (refractory). Drugs used in chemotherapy,... expand
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to treatment (refractory). Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as dinutuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Eflornithine blocks the production of chemicals called polyamines that are important in the growth of cancer cells. Giving eflornithine with irinotecan hydrochloride, temozolomide, and dinutuximab, may work better in treating patients with relapsed or refractory neuroblastoma. Type: Interventional Start Date: May 2019 |
Placement of Antibiotic Powder in Wounds During the Emergency Room
The University of Texas Health Science Center at San Antonio
Open Fracture
This is the first prospective controlled study to determine whether the topical application
of vancomycin powder reduces infection-related complications when applied to open fracture
injuries in the acute emergency department setting.
expand
This is the first prospective controlled study to determine whether the topical application of vancomycin powder reduces infection-related complications when applied to open fracture injuries in the acute emergency department setting. Type: Interventional Start Date: Oct 2020 |
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response...
Kura Oncology, Inc.
HRAS Gene Mutation
HNSCC
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study
evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will
assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS
mutations.... expand
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up. Type: Interventional Start Date: Nov 2018 |
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma...
National Cancer Institute (NCI)
Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in
treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600
mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help
repair... expand
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and temozolomide alone. Type: Interventional Start Date: Oct 2018 |
Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Canadian Cancer Trials Group
Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual
care that includes regional radiation therapy, with receiving no regional radiation therapy.
Researchers want to see if not giving this type of radiation treatment works as well at... expand
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. Type: Interventional Start Date: May 2018 |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors,...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Malignant Glioma
Recurrent Ependymoma
This phase II Pediatric MATCH trial studies how well PI3K/mTOR inhibitor LY3023414 works in
treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC
or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have... expand
This phase II Pediatric MATCH trial studies how well PI3K/mTOR inhibitor LY3023414 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have come back (recurrent) or do not respond to treatment (refractory). PI3K/mTOR inhibitor LY3023414 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Type: Interventional Start Date: Jul 2017 |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma,...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Low Grade Glioma
Malignant Glioma
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients
with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other
places in the body and have come back or do not respond to treatment with FGFR mutations.... expand
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Type: Interventional Start Date: Nov 2017 |
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Columbia University
Stroke
Objectives
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention
of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban... expand
Objectives - Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. - Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy. Type: Interventional Start Date: Jan 2018 |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Histiocytic Sarcoma
Juvenile Xanthogranuloma
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment
that is directed by genetic testing works in pediatric patients with solid tumors,
non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one
line... expand
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. Type: Interventional Start Date: Jul 2017 |